Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, outlines the current outlook of Waldenströms macroglobulinemia (WM), from hand-me-down to targeted approaches. The discovery of key growth and survival mutations, such as MYD88, has allowed the development of BTK inhibitors at the core of WM treatment. This video was recorded at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France.
Whole genome sequencing opens door for targeted Waldenström’s therapy
